Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015

22.07.2015

Results Demonstrate Statistically Significant Reduction of Beta Amyloid, Dose-Dependent Slowing of Clinical Decline and Acceptable Safety.

News overview

This website uses cookies, with the aim of ensuring that you have the best possible online experience. In using our website, you are giving your consent to the terms and conditions of our Privacy policy

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue